Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics
5 years ago

Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET)

Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET)
C. R. Sirtori, A. Sartore-Bianchi, C. Pavanello, V. De Gennaro Colonna, S. Siena, G. Mombelli, S. Castelnuovo, F. Rusconi
What is known and objective Hypertriglyceridaemia (HTG) is a potentially serious side effect of everolimus therapy. We here report a case of severe HTG in an everolimus-treated patient and provide recommendations for its management. Case summary The patient was a 70-year-old woman, being treated with everolimus for a pancreatic neuroendocrine tumour (pNET). She developed severe HTG to a maximum of 969 mg/dL after 22 months of therapy. Treatment with fenofibrate rapidly normalized triglyceride (TG) levels. What is new and conclusion Severe HTG may occur in everolimus-treated patients. Prescription of the appropriate therapy can allow patients to continue this medication. Treatment with everolimus induces severe hypertriglyceridemia, possibly decreasing lipoprotein lipase (LPL) activity, reducing degradation of apolipoprotein B100 (apoB100) and upregulating the adipocyte fatty acid-binding protein (aP2) expression. After treatment with fenofibrate 145 mg/day, triglycerides (TG) levels strikingly decrease by about 32%.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/jcpt.12588

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.